Featured Research

from universities, journals, and other organizations

Experimental Drug Decreases Age-Related Blood Vessel Stiffening

Date:
September 12, 2001
Source:
Johns Hopkins Medical Institutions
Summary:
An experimental drug may reverse stiffening of the cardiovascular system that occurs with aging, according to a national study led by Johns Hopkins physicians.

An experimental drug may reverse stiffening of the cardiovascular system that occurs with aging, according to a national study led by Johns Hopkins physicians.

In a group of older people with vascular stiffening, the drug, ALT-711, significantly reduced arterial pulse pressure, defined as the difference between systolic blood pressure (the upper number) and diastolic blood pressure (the lower number). It also improved the blood vessels' ability to stretch by about 14 percent. Results are to be reported in the Sept. 25 issue of Circulation, an American Heart Association journal, but were posted online Sept. 3. ALT-711 is manufactured by Alteon Inc., Ramsey, N.J.

Vascular stiffening and its related increase in the heart's workload is a "huge epidemiological problem," affecting about half of all individuals over age 60, says David A. Kass, M.D., lead author of the study and professor of medicine and biomedical engineering at Hopkins. "Many recent epidemiological studies have shown that pulse pressure is the leading risk factor for cardiovascular disease in the elderly," he says. Left untreated, the condition can lead to high blood pressure, congestive heart failure, heart attack and other disorders.

ALT-711 works by breaking up chemical links between sugar and proteins called advanced glycosylated (sugar-based) crosslink endproducts, or AGE. In the cardiovascular system, AGE results in a loss of artery elasticity. This leads to an increase in the blood pressure pulse and selective rise in the systolic pressure, putting patients at an increased risk of heart attack, heart failure and coronary artery disease.

The crosslinks form in patients with abnormal sugar control – such as diabetics – but also with normal aging. They particularly target long-lived proteins, like those that make up the structure of artery walls and are responsible for their ability to stretch. The more crosslinks, the stiffer the related tissues. This affects the cornea, bladder, arteries and possibly the heart. Diabetics face these problems earlier because of their altered body chemistry. These crosslinks also have recently been reported to affect neural function and may play a role in Alzheimer's disease.

"Prior drugs to treat this common type of blood pressure problem mostly have focused on lowering the mean or average pressure by relaxing the peripheral arteries that regulate resistance," says Kass. "ALT-711 appears to be different. It likely acts on the larger vessels that regulate stiffness. This may represent a novel therapeutic approach for patients with arterial stiffening associated with aging, diabetes and systolic hypertension."

During the trial, researchers at nine sites around the country studied 93 adults age 50 and up with measurably stiffened blood vessels and a systolic blood pressure of at least 140 mmHg. Patients took a drug tablet or a placebo once a day for eight weeks, during which researchers recorded their blood pressure, the flexibility or compliance of their arteries and blood flow through the heart, among other factors. ALT-711 was well tolerated in the patients who received the active drug.

Scientists are continuing to evaluate the medication and its ability to treat systolic hypertension in larger groups of patients.

Kass is a consultant to Alteon Inc. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

The study was supported by the National Institute on Aging and Alteon Inc. Other authors were Edward P. Shapiro, M.D., Miho Kawaguchi, M.D., and Anne R. Capriotti of Hopkins; Angelo Scuteri, M.D., Ph.D., and Edward G. Lakkata, M.D., of the NIA's Gerontology Research Center in Baltimore; and Robert C. deGroof, Ph.D., of Alteon Inc.

Kass, D.A., et al., "Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker," (Rapid Track) Circulation, 104: R8-R14.

Related Web sites:

Johns Hopkins' Division of Cardiology: http://www.cardiology.hopkinsmedicine.org

Alteon Inc.: http://www.alteonpharma.com


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "Experimental Drug Decreases Age-Related Blood Vessel Stiffening." ScienceDaily. ScienceDaily, 12 September 2001. <www.sciencedaily.com/releases/2001/09/010906072321.htm>.
Johns Hopkins Medical Institutions. (2001, September 12). Experimental Drug Decreases Age-Related Blood Vessel Stiffening. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2001/09/010906072321.htm
Johns Hopkins Medical Institutions. "Experimental Drug Decreases Age-Related Blood Vessel Stiffening." ScienceDaily. www.sciencedaily.com/releases/2001/09/010906072321.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins